Oncogene NRF2

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10337071
APP PUB NO 20110136246A1
SERIAL NO

13055697

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides a marker which can be used as an indicator for efficacy prediction of an mTOR related anticancer agent or prognostic prediction, and a novel anticancer agent. The present invention provides a method for efficacy evaluation of a cancer drug, and, specifically, a prediction method for the efficacy of an mTOR-related cancer drug by detecting NRF2 abnormality. In addition, the present invention provides a prognostic prediction method for cancer, and, specifically, a prediction method for the prognosis of cancer by detecting NRF2 abnormality. Furthermore, the present invention provides a novel anticancer agent that targets NRF2.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INFOCOM CORPORATION2-34-17 JINGUUMAE SHIBUYA-KU TOKYO 150-0001

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Saito, Shigeru Tokyo, JP 101 1092
Shibata, Tatsuhiro Tokyo, JP 6 47

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 2, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 2, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00